Evidence map›Paper›PMID 40465057›Full record

ReviewCurrent gastroenterology reports2025

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.

Sarah Rotondo-Trivette, William Jennings, David Fudman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sarah Rotondo-TrivetteDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX, USA.
William JenningsDepartment of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA.
David FudmanDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX, USA. david.fudman@utsouthwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice. RECENT

findingsThe last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events. IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.

Indexed as

Antibodies, MonoclonalInflammatory Bowel DiseasesInterleukin-23Antibodies, Monoclonal, HumanizedHumansUstekinumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedInterleukin-23UstekinumabCrohn’s diseaseGuselkumabInflammatory bowel diseaseInterleukin-23MirikizumabRisankizumabUlcerative ColitisUstekinumab

Identifiers

PMID40465057

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.